As concerns the EHF transcript variants, Sakamoto et al. [23] demonstrated that only EHF-SF variant abrogates ETS1-mediated activation of the ZEB1 promoter by promoting degradation of ETS1 proteins, thereby inhibiting the EMT phenotypes of cancer cells. The gene discussed is ZEB1; the disease is cancer.